Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct

N Saidenberg-Kermanac'h1, A Corrado, D Lemeiter

  • 1UPRES EA-3408 and Department of Rheumatology, Avicenne Hospital (AP-HP), Claude Bernard Foundation, Bobigny Medical School, Paris 13 University, Paris, France. nathalie.saidenberg@avc.ap-hop-paris.fr

Bone
|November 16, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Axial bone involvement in sarcoidosis has a good prognosis: Longitudinal study of a cohort of 48 patients.

Seminars in arthritis and rheumatism·2025
Same author

Interplay among sleep quality, dinner timing, and blood glucose control in users of advanced technologies: A study in a cohort of adults with type 1 diabetes.

Diabetes research and clinical practice·2025
Same author

A universal UHPLC-CAD platform for the quantification of polysaccharide antigens.

Scientific reports·2023
Same author

Subclinical coronary atherosclerosis, detected by computer tomography with coronary calcium score, and the occurrence of major cardiovascular events at 5 years of follow-up in a cohort of patients with systemic sclerosis.

European journal of internal medicine·2023
Same author

Postprandial glucose variability in type 1 diabetes: The individual matters beyond the meal.

Diabetes research and clinical practice·2022
Same author

Osteoblast role in the pathogenesis of rheumatoid arthritis.

Molecular biology reports·2021

Osteoprotegerin (OPG) and anti-TNF-alpha antibodies prevent bone loss in rheumatoid arthritis models by reducing bone resorption and preserving bone formation, respectively. Combining these therapies may offer enhanced protection against bone loss in inflammatory diseases.

Area of Science:

  • Immunology
  • Rheumatology
  • Bone Biology

Background:

  • Rheumatoid arthritis (RA) is characterized by bone loss driven by cytokines like RANKL and TNF-alpha.
  • Osteoprotegerin (OPG) inhibits bone resorption, while anti-TNF-alpha antibodies target inflammation.
  • The impact of anti-TNF-alpha antibodies on bone loss in RA models remains unclear.

Purpose of the Study:

  • To investigate the effects of OPG and anti-TNF-alpha antibodies on inflammation and bone remodeling.
  • To evaluate the efficacy of OPG and anti-TNF-alpha antibodies, alone and in combination, in a collagen-induced arthritis (CIA) mouse model.

Main Methods:

  • DBA/1 mice were induced with collagen-induced arthritis (CIA).
  • Mice were treated with OPG-Fc, anti-TNF-alpha antibodies, both, or saline.

Related Experiment Videos

  • Bone mineral density (BMD), urinary deoxypyridinoline (D-pyr), and histomorphometric parameters were assessed.

    • Main Results:

    • Anti-TNF-alpha antibodies reduced clinical and histological arthritis scores.
    • Both OPG and anti-TNF-alpha antibodies increased BMD and reduced bone resorption markers (D-pyr).
    • OPG increased bone volume and decreased bone formation rate, while anti-TNF-alpha antibodies preserved bone formation.

    Conclusions:

    • Systemic OPG and anti-TNF-alpha antibody therapies prevent bone loss in CIA mice via distinct mechanisms.
    • OPG reduces bone resorption, and anti-TNF-alpha antibodies preserve bone formation.
    • Combination therapy may be beneficial for preventing bone loss in inflammatory diseases.